oxiracetam has been researched along with Stroke in 5 studies
oxiracetam: structure in first source
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, we investigated the therapeutic effects of combined bone marrow stromal cells (BMSCs) and oxiracetam treatments on acute cerebral ischemia/reperfusion (I/R) injury." | 7.91 | Combined bone marrow stromal cells and oxiracetam treatments ameliorates acute cerebral ischemia/reperfusion injury through TRPC6. ( Li, Z; Pan, Y; Sun, R; Wang, J, 2019) |
| "Oxiracetam may have a modest effect on preventing cognitive decline." | 5.69 | Efficacy and safety of oxiracetam in patients with vascular cognitive impairment: A multicenter, randomized, double-blinded, placebo-controlled, phase IV clinical trial. ( Bae, HJ; Cha, JK; Chang, DI; Cho, HJ; Cho, KH; Choi, JC; Chung, JW; Heo, JH; Heo, SH; Jung, KH; Kang, Y; Kim, C; Kim, DE; Kim, EG; Kim, HY; Kim, JG; Kim, YI; Kwon, JH; Lee, J; Lee, JH; Lee, KB; Lee, SJ; Lee, YB; Lee, YS; Lim, JS; Moon, WJ; Oh, KM; Oh, MS; Park, H; Park, HT; Park, JH; Park, JM; Park, JW; Park, KY; Park, MS; Park, TH; Rha, JH; Sung, SM; Yi, S, 2023) |
| "In this study, we use the middle cerebral artery occlusion/reperfusion (MCAO/R) model in rats and oxygen glucose deprivation/reoxygenation (OGD/R) model in fetal rat primary cortical neurons to investigate whether and how S-oxiracetam (S-ORC) protect brain injury from ischemic stroke." | 5.48 | S-oxiracetam ameliorates ischemic stroke induced neuronal apoptosis through up-regulating α7 nAChR and PI3K / Akt / GSK3β signal pathway in rats. ( Fan, W; Fang, W; Fu, Y; He, S; Huang, L; Li, X; Li, Y; Xie, Z, 2018) |
| " The clinical efficacy of nicergoline combined with oxiracetam in the treatment of vascular cognitive impairment after stroke was analyzed." | 5.34 | Clinical efficacy and safety of nicergoline combined with oxiracetam in the treatment of vascular cognitive impairment. ( Ma, Z; Qiao, P; Wang, B; Zhong, L, 2020) |
| " In this study, we investigated the therapeutic effects of combined bone marrow stromal cells (BMSCs) and oxiracetam treatments on acute cerebral ischemia/reperfusion (I/R) injury." | 3.91 | Combined bone marrow stromal cells and oxiracetam treatments ameliorates acute cerebral ischemia/reperfusion injury through TRPC6. ( Li, Z; Pan, Y; Sun, R; Wang, J, 2019) |
| "In this study, we use the middle cerebral artery occlusion/reperfusion (MCAO/R) model in rats and oxygen glucose deprivation/reoxygenation (OGD/R) model in fetal rat primary cortical neurons to investigate whether and how S-oxiracetam (S-ORC) protect brain injury from ischemic stroke." | 1.48 | S-oxiracetam ameliorates ischemic stroke induced neuronal apoptosis through up-regulating α7 nAChR and PI3K / Akt / GSK3β signal pathway in rats. ( Fan, W; Fang, W; Fu, Y; He, S; Huang, L; Li, X; Li, Y; Xie, Z, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lim, JS | 1 |
| Lee, J | 2 |
| Kang, Y | 1 |
| Park, HT | 1 |
| Kim, DE | 1 |
| Cha, JK | 1 |
| Park, TH | 1 |
| Heo, JH | 1 |
| Lee, KB | 1 |
| Park, JM | 1 |
| Oh, MS | 1 |
| Kim, EG | 1 |
| Chang, DI | 1 |
| Heo, SH | 1 |
| Park, MS | 1 |
| Park, H | 1 |
| Yi, S | 1 |
| Lee, YB | 1 |
| Park, KY | 1 |
| Lee, SJ | 1 |
| Kim, JG | 1 |
| Cho, KH | 1 |
| Rha, JH | 1 |
| Kim, YI | 1 |
| Lee, JH | 1 |
| Choi, JC | 1 |
| Oh, KM | 1 |
| Kwon, JH | 1 |
| Kim, C | 1 |
| Park, JH | 1 |
| Jung, KH | 1 |
| Sung, SM | 1 |
| Chung, JW | 1 |
| Lee, YS | 1 |
| Kim, HY | 1 |
| Cho, HJ | 1 |
| Park, JW | 1 |
| Moon, WJ | 1 |
| Bae, HJ | 1 |
| Wang, B | 1 |
| Zhong, L | 1 |
| Qiao, P | 1 |
| Ma, Z | 1 |
| Huang, L | 2 |
| Shang, E | 1 |
| Fan, W | 2 |
| Li, X | 2 |
| Li, B | 1 |
| He, S | 2 |
| Fu, Y | 2 |
| Zhang, Y | 1 |
| Li, Y | 2 |
| Fang, W | 2 |
| Xie, Z | 1 |
| Wang, J | 1 |
| Sun, R | 1 |
| Li, Z | 1 |
| Pan, Y | 1 |
2 trials available for oxiracetam and Stroke
| Article | Year |
|---|---|
Efficacy and safety of oxiracetam in patients with vascular cognitive impairment: A multicenter, randomized, double-blinded, placebo-controlled, phase IV clinical trial.
Topics: Cognitive Dysfunction; Double-Blind Method; Humans; Pyrrolidines; Quality of Life; Stroke; Treatment | 2023 |
Clinical efficacy and safety of nicergoline combined with oxiracetam in the treatment of vascular cognitive impairment.
Topics: Adult; Aged; Aged, 80 and over; Cognitive Dysfunction; Drug Therapy, Combination; Female; Humans; Ma | 2020 |
3 other studies available for oxiracetam and Stroke
| Article | Year |
|---|---|
S-oxiracetam protect against ischemic stroke via alleviating blood brain barrier dysfunction in rats.
Topics: Animals; Atenolol; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cla | 2017 |
S-oxiracetam ameliorates ischemic stroke induced neuronal apoptosis through up-regulating α7 nAChR and PI3K / Akt / GSK3β signal pathway in rats.
Topics: Animals; Apoptosis; Brain Ischemia; Cell Survival; Infarction, Middle Cerebral Artery; Male; Neurons | 2018 |
Combined bone marrow stromal cells and oxiracetam treatments ameliorates acute cerebral ischemia/reperfusion injury through TRPC6.
Topics: Animals; Bone Marrow Transplantation; Brain Ischemia; Calpain; Cerebral Cortex; Cyclic AMP Response | 2019 |